Publications by authors named "D Koya"
Angiopoietin-like 4 (ANGPTL4), a key protein involved in lipoprotein metabolism, has diverse effects. There is an association between Angptl4 and diabetic kidney disease; however, this association has not been well investigated. We show that both podocyte- and tubule-specific ANGPTL4 are crucial fibrogenic molecules in diabetes.
View Article and Find Full Text PDFAutophagy plays a complex role in breast cancer cell survival, metastasis, and chemotherapeutic resistance. Dipeptidyl peptidase (DPP)-4, a therapeutic target for type 2 diabetes mellitus, is also involved in autophagic flux. The potential influence of DPP-4 suppression on cancer biology remains unknown.
View Article and Find Full Text PDFArticle Synopsis
- In the FIDELIO-DKD study, finerenone was shown to significantly improve heart and kidney health in patients with chronic kidney disease and type 2 diabetes, especially in the Asian population.
- A post hoc analysis of 1,327 Asian patients found that finerenone reduced risks of kidney failure and cardiovascular issues compared to a placebo.
- The benefits and safety of finerenone were consistent across both Asian and non-Asian patients, suggesting its effectiveness is universal.
Aim: To assess the effect of finerenone on the risk of cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes, with and without obesity.
Materials And Methods: A post hoc analysis of the prespecified pooled FIDELITY dataset assessed the association between waist circumference (WC), composite cardiovascular and kidney outcomes, and the effects of finerenone. Participants were stratified by WC risk groups (representing visceral obesity) as low-risk or high-very high-risk (H-/VH-risk).
Aims/introduction: Linagliptin is a selective dipeptidyl peptidase (DPP)-4 inhibitor capable of successfully regulating blood glucose levels. The cardiovascular protective effects of several DPP-4 inhibitors have been shown in preclinical studies; however, the detailed influence of DPP-4 inhibitors on diabetic pathological alterations in cardiac tissue has not yet been elucidated.
Materials And Methods: We combined laboratory-based experiments and bioinformatics techniques to identify suitable candidate targets with significant biological pathways.